Genmab Announces Financial Results for the First Half of 2026

Genmab reported 1H 2026 revenue of $2,051M, up $411M (+25%) from $1,640M, driven by higher DARZALEX and Kesimpta royalties and stronger EPKINLY net product sales (+48% to $312M). Royalty revenue rose to $1,708M (+$330M, +24%), while adjusted operating profit increased to $656M (+$102M, +18%). The company also updated full-year 2026 guidance, raising revenue to $4,325–$4,525M (vs prior $4,065–$4,395M) and adjusted operating profit to $1,065–$1,385M (vs $900–$1,400M), supported by improved royalty and net sales expectations alongside positive Phase 3 epcoritamab data in relapsed/refractory DLBCL.

Analysis

The cleanest read-through is that Genmab is transitioning from a royalty levered story into a hybrid platform with enough self-funded pipeline optionality to compress perceived risk. That matters because the market usually pays up for late-stage oncology only when the cash engine is visible; here, improving royalty durability can support a higher multiple even before the new assets hit revenue. The immediate beneficiary is GMAB, while JNJ and NVS see their underlying franchises validated by stronger partner sell-through, though they are forced to pay away more economics to Genmab.

The less obvious loser is ABBV: higher EPKINLY uptake helps the asset narrative, but the economics increasingly look like a mature co-commercialized profit share rather than a clean margin contributor. If uptake continues, the stock should trade more on the quality of the oncology mix than on headline sales, which is a subtle headwind versus simpler proprietary assets. For MRUS and smaller bispecific names, the second-order effect is multiple pressure: investors tend to rotate toward companies with both clinical de-risking and royalty support, which raises the bar for pre-profit peers.

The key catalyst path is not the PFS headline itself, but whether management can convert it into accelerated sequencing for label expansion and earlier-line adoption over the next 1-3 quarters. The contrarian risk is that operating leverage is weaker than the top line suggests: higher R&D and launch spend are already absorbing much of the revenue lift, so a guidance beat without margin expansion may not justify a rerating. Falsifiers are simple: if next-quarter commentary shows slower EPKINLY traction, if partner sales decelerate, or if the new data fail to move regulators toward broader use, the current optimism should fade quickly.

Key Decisions for Investors

• Long GMAB on pullbacks over the next 1-3 weeks; target is a re-rating on durable royalty visibility plus pipeline de-risking. Risk/reward is attractive if the market starts valuing the company as a cash-generative oncology platform rather than a single-asset clinical story.
• Pair trade: long GMAB / short XBI for a 1-3 month horizon. The thesis is that capital should favor profitable, royalty-backed biotech over cash-burning platform names if clinical read-throughs remain positive.
• Reduce or underweight ABBV versus large-cap pharma peers into strength over the next quarter. The incremental EPKINLY economics look less margin-accretive than the sales growth suggests, so ABBV may be a relative laggard unless pipeline assets offset the profit-share drag.
• Watch JNJ as a lower-beta beneficiary, but do not chase immediately; use it as a defensive royalty-quality holding only if DARZALEX growth stays above the current run-rate for another quarter. Falsifier: any sign of deceleration in partner sell-through.
• Set an alert on MRUS and similar bispecific developers for relative weakness if GMAB continues to execute. If investors decide the winner is the company with both clinical proof and self-funding, smaller peers could see multiple compression despite no direct competitive event.